摘要
Passage of the capsule endoscope to the colon occurs in only approximately three quarters of patients. This study assessed factors that might influence the completeness of small-bowel transit, including orally administered metoclopramide. Clinical and procedural parameters were recorded prospectively for 150 patients undergoing capsule endoscopy. Metoclopramide was not administered to the first 83 patients (Group 1) but was given orally (10 mg) to the subsequent 67 (Group 2). Small-bowel transit was complete in 63 patients in Group 1 (76%). Gastric transit time was significantly longer when the capsule did not reach the colon than when it did (114.9 ±32.6 minutes vs. 26.6 ±2.9 minutes; p = 0.007). Small-bowel transit time also was longer. The likelihood of complete small-bowel passage was not predicted by any clinical or procedural factor. In Group 2 (metoclopramide), the capsule reached the colon in 65 (97%) patients (OR 10.3: 95%CI[2.32, 93.55], p < 0.001). This improvement was associated with a significant reduction in gastric transit time (47.9 ±9.0 minutes vs. 30.8 ±7.5 minutes; p = 0.025). Metoclopramide increases the likelihood of a complete small-bowel examination in patients undergoing capsule endoscopy.
Passage of the capsule endoscope to the colon occurs in only approximately three quarters of patients. This study assessed factors that might influence the completeness of small-bowel transit, including orally administered metoclopramide. Clinical and procedural parameters were recorded prospectively for 150 patients undergoing capsule endoscopy. Metoclopramide was not administered to the first 83 patients (Group 1) but was given orally (10 mg) to the subsequent 67 (Group 2). Small-bowel transit was complete in 63 patients in Group 1 (76%). Gastric transit time was significantly longer when the capsule did not reach the colon than when it did (114.9 ±32.6 minutes vs. 26.6 ±2.9 minutes; p = 0.007). Small-bowel transit time also was longer. The likelihood of complete small-bowel passage was not predicted by any clinical or procedural factor. In Group 2 (metoclopramide), the capsule reached the colon in 65 (97%) patients (OR 10.3: 95%CI[2.32, 93.55], p < 0.001). This improvement was associated with a significant reduction in gastric transit time (47.9 ±9.0 minutes vs. 30.8 ±7.5 minutes; p = 0.025). Metoclopramide increases the likelihood of a complete small-bowel examination in patients undergoing capsule endoscopy.
